Phase III HIV trial results send Canadian biotech soaring

11 November 2016
2019_biotech_test_vial_discovery_big

A Canadian biotech company closed nearly 8% up on Thursday at C$3.35 on the back of Phase III results on ibalizumab in patients with multi-drug resistant (MDR) HIV-1.

Theratechnologies (TSX: TH) announced that it had been notified by its partner, the Taiwanese biotechnology firm TaiMed Biologics (4147: TT), of the preliminary results for the safety and efficacy secondary endpoints of the 24-week Phase III trial.

The findings show that ibalizumab maintains significant reduction of viral load in patients with MDR HIV-1 over 24 weeks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology